Neil Kumar sold $5.0M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 80,000 shares at an average of $62.29, traded Nov 6, 2025, filed Nov 10, 2025.
Score components
- +25RoleCEO
- +25Trade size$5.0M at market
- 0Share of holdings soldSold 1.7% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-25-000302, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -12,576 | $62.91 | $791k | 4,625,871 | Nov 10, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,324 | $63.55 | $465k | 4,618,547 | Nov 10, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -100 | $64.39 | $6,439 | 4,618,447 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -12,492 | $61.14 | $764k | 4,605,955 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,308 | $61.87 | $452k | 4,598,647 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -200 | $62.81 | $13k | 4,598,447 | Nov 10, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -12,529 | $62.91 | $788k | 823,157 | Nov 10, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,371 | $63.56 | $468k | 815,786 | Nov 10, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -100 | $64.39 | $6,439 | 815,686 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -12,234 | $61.13 | $748k | 803,452 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,546 | $61.87 | $467k | 795,906 | Nov 10, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -220 | $62.79 | $14k | 795,686 | Nov 10, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.5M 80,000 shares | -12% | |
| 35Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $624k 8,671 shares | -54% | |
| 40Moderate | BridgeBio Pharma, Inc. | Andrea Ellis director | $4.2M 64,921 shares | -78% | |
| 40Moderate | BridgeBio Pharma, Inc. | Hannah Valantine director | $1.7M 25,484 shares | -77% | |
| 21Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $132k 2,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $2.0M 28,053 shares | -11% | |
| 16Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $38k 510 shares | -0% | |
| 27Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $755k 10,000 shares | -46% | |
| 42Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $1.0M 13,600 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.